DOT1L and acute lymphoblastic leukemia: Pinometostat (EPZ-5676), an inhibitor of the disruptor of telomeric silencing-1 gene (DOT1L), has been assessed in phase 1 dose-escalation studies in pediatric and adult patients with relapsed and refractory AML and ALL [2, 3].